List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Chugai Pharmaceutical Co Ltd
InflaRx NV
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Noxxon Pharma AG
Ophthotech Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
AcPepA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AOND-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bikaciomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemdisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coversin LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mubodi - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit Complement C5 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101295 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab next generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturl Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Coversin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
Featured News & Press Releases
Oct 04, 2018: Ophthotech completes patient recruitment as planned for its phase 2b clinical trial of Zimura monotherapy for geographic atrophy secondary to dry age-related macular degeneration
Sep 30, 2018: Akari Therapeutics announces new clinical data in post-transplant thrombotic microangiopathies
Sep 28, 2018: Ra Pharma reports positive data from Phase lb trial of zilucoplan
Sep 24, 2018: Alexion announces successful phase 3 PREVENT Study Of soliris (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sep 12, 2018: Akari Therapeutics announces new preclinical rheumatoid arthritis data and new clinical data in patients with bullous pemphigoid, highlighting potential advantages of coversin’s bifunctiol activity inhibiting both the complement and leukotriene inflamma
Sep 05, 2018: Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Aug 28, 2018: InflaRx To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclol Antibody IFX-1
Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturl hemoglobinuria in the US
Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program
Jul 02, 2018: Alexion Pharma Korea’s aHUS therapy Soliris gains coverage
Jun 28, 2018: InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturl Hemoglobinuria (PNH) In The European Union (EU)
Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturl Hemoglobinuria in the U.S.
Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturl Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer